
Microbot Medical (MBOT) Stock Forecast & Price Target
Microbot Medical (MBOT) Analyst Ratings
Bulls say
Microbot Medical Inc. has demonstrated positive preclinical results that have advanced its LIBERTY® Robotic Surgical System into human trials, showcasing a notable 95% success rate in targeting specific vascular areas during catheterizations. The company has submitted an Investigational Device Exemption (IDE) application to the FDA, reflecting confidence in its technology and its potential to innovate within the surgical landscape. Additionally, with all six LIBERTY systems achieving 100% usability and technical success in studies, Microbot Medical is well-positioned to improve surgical outcomes and gain competitive advantages through its strong patent portfolio.
Bears say
Microbot Medical Inc faces significant operational and financial uncertainties, primarily stemming from its reliance on the successful clinical trials and regulatory approval of its flagship product, LIBERTY. The company reported a net loss of $10.7 million, equating to a loss of $1.05 per share, which underscores the financial challenges it encounters as it seeks to commercialize its technologies. Additionally, risks associated with establishing partnerships for market penetration and the potential for dilution further contribute to a negative outlook on the firm's financial stability and growth prospects.
This aggregate rating is based on analysts' research of Microbot Medical and is not a guaranteed prediction by Public.com or investment advice.
Microbot Medical (MBOT) Analyst Forecast & Price Prediction
Start investing in Microbot Medical (MBOT)
Order type
Buy in
Order amount
Est. shares
0 shares